English 
Home About STOP Members UNIVDUN

University of Dundee

Logo

University of Dundee
School of Medicine, Division of Medical Sciences, Centre for Neuroscience
Centre for Child Health, 19
Dudhope Terrace
DD3 6HH Dundee
United Kingdom

Homepage

Project leader

Dr David Coghill

Dr David Coghill

Phone: +44 (0) 1382 204004
Fax: +44 (0) 1382 346555

Project staff

Prof Roland Wolf OBE

Phone: +44 (0) 1382 632621

Dr Gillian Smith

Phone: +44 (0) 1382 425588

Institute presentation

Description of organisation:

The University of Dundee is a leading UK institute for medical research. The Dundee Developmental Research Group (DDRG, headed up by Dr David Coghill) specializes in high quality clinical care and research into various child and adolescent neuropsychiatric disorders including ADHD, Conduct Disorder, Depression and Autism Spectrum Disorders. This group sits within the Centre for Neuroscience which includes all of the Universities’ mental health and basic neuroscience research. The DDRG conducts a wide range of research ranging from laboratory based molecular genetics and pharmacogenomics, through neuropsychology and neuropsycho-pharmacology to studies into quality of life and clinical trials. The group’s clinical research is conducted alongside the local Child and Adolescent Mental Health Services with whom we share staff and have strong links. This service receives around 1000 new referrals each year. Clinical trials are conducted within a dedicated children’s clinical trial facility supported by the Scottish Medicines for Children Research Network. As such, research into the efficacy and safety of medication treatment for psychiatric disorders in children and adolescents is on the priority list of research activities.

Previous experience:

The UNIVDUN (Coghill) have been involved, as Principle Investigator, in many international collaborations, including multi-site international medication trials (e.g. Bangs et al, 2006, Sonuga-Barke et al 2007, Wilson et al 2006) and large scale European observational studies (e.g. Coghill et al 2006) and neuropsychopharmacological studies (e.g. Coghill et al 2007). The Centre for Neuroscience has experience in working within FP6 Integrated Projects. (Wolf and Matthews) have led and collaborated in many international studies into depression and pharmacogenomics.

Profile of staff members:

David Coghill (MB ChB MRCPsych) is child and adolescent psychiatrist, and senior lecturer in Child and Adolescent Psychiatry, at the University of Dundee and Honorary Consultant Child and Adolescent Psychiatrist in the Tayside Child and Adolescent Mental Health Service. He has been involved in several trials in children and adolescents with ADHD and Conduct Disorder and is currently the global lead investigator for two large multinational clinical trials. He is also active in genetic, neuropsychological, neuropsychopharmacological and quality of life research.

C Roland Wolf (PhD) Professor and Head of Biomedical Sciences Research Division at the University of Dundee, Honorary Director, Cancer Research UK Molecular Pharmacology Unit. He is a world authority on pharmacogenomics working across several disease areas. Recent work includes studies to identify genetic factors associated with variability in response to antidepressants.

Research with relevance to the project:

  1. Matthews, K., Coghill, D., & Rhodes, S. 2008, "Neuropsychological functioning in depressed adolescent girls", J.Affect.Disord.
  2. Wilkie, M. J., Smith, G., Day, R. K., Matthews, K., Smith, D., Blackwood, D., Reid, I. C., & Wolf, C. R. 2009, "Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy", Pharmacogenomics J., vol. 9, no. 1, pp. 61-70.
  3. Wilkie, M. J., Smith, D., Reid, I. C., Day, R. K., Matthews, K., Wolf, C. R., Blackwood, D., & Smith, G. 2007, "A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression", Pharmacogenet.Genomics, vol. 17, no. 3, pp. 207-215.
  4. Graham, J. & Coghill, D. 2008, "Adverse Effects of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder : Epidemiology, Prevention and Management", Cns Drugs, vol. 22, no. 3, pp. 213-237.
  5. Anderson, I. M., Ferrier, I. N., Baldwin, R. C., Cowen, P. J., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R. H., Peveler, R. C., Scott, J., & Tylee, A. 2008, "Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines", J.Psychopharmacol., vol. 22, no. 4, pp. 343-396.
Top